Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells

Cytokine

Volumn 33, Issue 6, 2006, Pages 323-336

  Jorcyk, Cheryl L ^a   Holzer, Ryan G ^b   Ryan, Randall E ^c  

^a BOISE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Boise VA Medical Center   (United States)

Author keywords

Breast cancer; Detachment; Invasion; Metastasis; OSM

Indexed keywords

BISINDOLYLMALEIMIDE; CATHEPSIN D; CATHEPSIN L; MITOGEN ACTIVATED PROTEIN KINASE; ONCOSTATIN M; PROTEIN KINASE C; PROTEINASE; UO 126;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INVASION; CELL AGGREGATION; CELL MIGRATION; CELL SECRETION; CELL ULTRASTRUCTURE; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYSOSOME MEMBRANE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CYTOKINES; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; ONCOSTATIN M;

EID: 33745441229     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.03.004     Document Type: Article

References (82)

1. Bruce A.G., Rose T.M., Linsley P.S., and Wallace P.M. Oncostatin M. In: Aggarwal B.B. (Ed). Human cytokines, handbook for basis and clinical research (1996), Blackwell Science, Inc., JU Gutterman 361-383
2. Rose T.M., and Bruce A.G. Oncostatin M is a member of a cytokine family that includes leukemia inhibitory factor, granulocyte colony-stimulating factor, and interleukin-6. Proc Natl Acad Sci U S A 91 (1994) 7109-7113
3. Zhang X.G., Gu J.J., Lu Z.Y., Yasukawa K., Yancopoulos G.D., Turner K., et al. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer GP130. J Exp Med 179 4 (1994) 1337-1342
4. Bruce A.G., Linsley P.S., and Rose T.M. Oncostatin M. Prog Growth Factor Res 4 (1992) 157-170
5. Vos J.P., Gard A.L., and Pfeiffer S.E. Regulation of oligodendrocyte cell survival and differentiation by ciliary neurotrophic factor, leukemia inhibitory factor, oncostatin M, and interleukin-6. Perspect Dev Neurobiol 4 (1995) 39-52
6. Mosley B., DeImus C., Friend D., Boiani N., Thoma B., Park L.S., et al. Dual oncostatin M (OSM) receptors. J Biol Chem 271 (1996) 32635-32643
7. Thomas B., Bird T.A., and Friend D.J. Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J Biol Chem 269 (1994) 6215-6222
8. Zarling J.M., Shoyab M., Marquardt H., Hanson M.B., Lioubin M.N., and Todare G.J. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci U S A 83 24 (1986) 9739-9743
9. Ryan RE, Liu J, Wang M, Sahin A, Vestal RE. The immunocytochemical localization of oncostatin M to tumor associated macrophages and polymorphonuclear leukocytes. From AACR Meeting, abstract #1053, 1998 [submitted for publication].
10. Grenier A., Dehoux M., Boutten A., Arde-Vicioso M., Durand G., Gourgerot-Pocidalo M.A., et al. Oncostatin M production and regulation by human polymorphonuclear neutrophils. Blood 93 (1999) 1413-1421
11. Miles S.A., Martinez M.O., Rezai A., Magpantay L., Kishimoto T., Nakamura S., et al. Oncostatin M as a potent mitogen for AIDS Kaposi's sarcoma-derived cells. Science 255 (1992) 1432-1434
12. Cai J., Gill P.S., Nasood R., Chandrasoma P., Jung B., Law R.E., et al. Oncostatin-M is an autocrine growth factor in Kaposi's sarcoma. Am J Pathol 145 1 (1994) 74-79
13. Schrell U.M., Koch H.U., Marchalek R., Schrauzer T., Anders M., Adams E., et al. Formation of autocrine loops in human cerebral meningioma tissue by leukemia inhibitory factor, interleukin-6 and oncostatin M: inhibition of meningioma cell growth in vitro by recombinant oncostatin-M. J Neurosurg 88 (1998) 541-548
14. Liu J., Hadjokas N., Mosley B., Estrov Z., Spence M.J., and Vestal R.E. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine 10 (1998) 295-302
15. Fitzpatrick W.C., Gompper P.T., Ochs V., Bolton-Hansen M., Zarling J., Malik N., et al. Regulation of cell growth by recombinant oncostatin M. Growth Factors 2 (1990) 157-165
16. Nair B.C., DeVico A.L., Nakamura S., Copeland T.D., Chen Y., Patel A., et al. Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science 255 (1992) 1430-1432
17. Koskela K., Pelliniemi T.T., Pelliniemi L.J., Remes K., Sodestrom K.O., Punnonen K., et al. Autocrine production and synergistic growth-promoting activity of interleukin-6 and oncostatin M in a new human myeloma cell line Tu-1. Acta Haematol 107 (2002) 23-28
18. Colella R., and Casey S.F. Decreased activity of cathepsins L + B and decreased invasive ability of PC3 prostate cancer cells. Biotech Histochem 78 (2003) 101-108
19. Tedone T., Correale M., Barbarossa G., Casavola V., Paradiso A., and Reshkin S.J. Release of the aspartyl protease cathepsin D is associated with and facilitates human breast cancer cell invasion. FASEB J 11 10 (Aug 1997) 785-792
20. Holzer R.G., Ryan R.E., Tommack M., Schlekeway E., and Jorcyk C.L. Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2. Clin Exp Metastasis 21 (2004) 167-176
21. Barille S., Akhoundi C., Collette M., Mellerin M.P., Rapp M.J., Harousseaun J.L., et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 90 4 (1997) 1649-1655
22. Varghese S., Yu K., and Canalis E. Leukemia inhibitory factor and oncostatin M stimulates collagenase-3 expression in osteoblasts. Am J Physiol 276 (1999) E465-E471
23. Damiens C., Grimaud E., Rousselle A.V., Charrier C., Fortun Y., Heymann D., et al. Cysteine protease production by human osteosarcoma cells (MG63, SAOS2) and its modulation by soluble factors. Cytokine 12 (2000) 539-542
24. Vasse M., Pourtau J., Trochon V., Muraine M., Vannier J., Lu H., et al. Oncostatin M inducing angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol 19 (1999) 1835-1842
25. Tamm I., Cardinale I., Krueger J.G., Murphy J., May L., and Sehgal P.B. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J Exp Med 170 (1989) 1649-1669
26. Tamm I., Kikuchi T., Cardinale I., and Krueger J.G. Cell-adhesion-disrupting action of interleukin 6 in human ductal breast carcinoma cells. Proc Natl Acad Sci U S A 91 (1994) 3329-3333
27. Sehgal P.B., and Tamm I. Interleukin-6 enhances motility of breast cancer cells. Cancer Invest 8 6 (1990) 661-663
28. Tamm I., Cardinale I., and Murphy J.S. Decreased adherence of interleukin 6-treated breast carcinoma cells can lead to separation from neighbors after mitosis. Proc Natl Acad Sci U S A 88 (1991) 4414-4418
29. Sehgal P.B., and Tamm I. Interleukin-6 enhances motility of breast carcinoma cell. In: Goldberg I.D. (Ed). Cell motility factors (1991), Birkhauser Verlag, Basel/Switzerland 178-193
30. Zhang F., Li C., Halfter H., and Liu J. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 22 (2003) 894-905
31. Liu J., Spence M.J., Wallace P.M., Forcier K., Hellstrom I., and Vestal R.E. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene. Cell Growth Differ 8 (1997) 667-676
32. Thoma B., Bird T.A., Friend D.J., Gearing D.P., and Dower S.K. Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J Biol Chem 269 (1994) 6215-6222
33. Mosley B., De Imus C., Friend D., Boiani N., Thoma B., Park L.S., et al. Dual oncostatin M (OSM) receptors: cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 271 (1996) 32635-32643
34. Douglas A.M., Grant S.L., Goss G.A., Clouston D.R., Sutherland R.L., and Begley C.G. Oncostatin M induces the differentiation of breast cancer cells. Int J Cancer 5 (1998) 64-73
35. Boyer B., Valles A.M., and Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 60 8 (Oct 2000) 1091-1099
36. Bhowmick N.A., Ghiassi M., Bakin A., Aakre M., Lundquist C.A., Engel M.E., et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12 (2001) 27-36
37. Korzus E., Nagase H., Rydell R., and Travis J. The mitogen activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J Biol Chem 272 2 (1997) 1188-1196
38. Zhang F., Li C., Halfter H., and Liu J. Delineating an oncostatin M-activated STAT signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 22 (2003) 894-905
39. Auguste P., Guillet C., Fourcin M., Olivier C., Veziers J., Pouplard-Barthelaix A., et al. Signaling of type II oncostatin M receptors. J Biol Chem 272 (1997) 15760-15764
40. Sliva D., English D., Lyons D., and Lloyd F.P. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB. Biochem Biophys Res Commun 290 (2002) 552-557
41. Ge X., Fu Y.M., and Meadows G.G. U0126, a mitogen-activated protein kinase inhibitor, inhibits, the invasion of human A375 melanoma cells. Cancer Lett 179 (2002) 133-140
42. Li C., Ahlborn T.E., Kraemer F.B., and Liu J. Oncostatin M-induced growth inhibition and morphological changes of MDA-MB231 breast cancer cells are abolished by blocking the MEK/ERK signaling pathway. Breast Cancer Res Treat 66 (2001) 111-121
43. Li C., Ahlborn T.E., Tokita K., Boxer L., Noda A., and Liu J. The critical role of the PE21 element in oncostatin M-mediated transcriptional repression of the p53 tumor suppressor gene in breast cancer cells. Oncogene 20 (2001) 8193-8202
44. Li W., Dehnade F., and Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 166 (2001) 3491-3498
45. Gagnoux-Palacios L., Allegra M., Spirito F., Pommeret O., Romero C., Ortonne J.P., et al. The short arm of the laminin gamma2 chain plays a pivotal role in the incorporation of laminin 5 into the extracellular matrix and in cell adhesion. J Cell Biol 153 (2001) 835-850
46. Patarroyo M., Tryggvason K., and Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol 12 (2002) 197-207
47. Badache A., and Hynes N. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 61 (2001) 383-391
48. Bohm I., and Schild H. Apoptosis: the complex scenario for a silent cell death. Mol Imaging Biol 5 (2003) 2-14
49. Kohn K.W., Erickson L.C., Ewig R.A., and Friedman C.A. Fractionation of DNA from mammalian cells by alkaline elution. Biochemistry 15 (1976) 4629-4637
50. Swenberg J.A., Petzold G.L., and Harbach P.R. In vitro DNA damage/alkaline elution assay for predicting carcinogenic potential. Biochem Biophys Res Commun 20 (1976) 732-738
51. Hartley J.A., Gibson N.W., Zwelling L.A., and Yuspa S.H. Association of DNA strand breaks with accelerated terminal differentiation in mouse epidermal cells exposed to tumor promoters. Cancer Res 45 (1985) 4864-4870
52. Stout D.L., and Becker F.F. Progressive DNA damage in hepatic nodules during 2-acetylaminofluorene carcinogenesis. Cancer Res 40 (1980) 1269-1273
53. Rochefort H., Garcia M., Glonda M., Laurant V., Liaudet E., Rey J.M., et al. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 291 2 (2000) 157-170
54. McCawley L.J., and Matrisian L.M. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6 (2000) 149-156
55. Sloane B.F., and Honn K.V. Cysteine proteinases and metastasis. Cancer Metastasis Rev 3 (1984) 249-263
56. Rha S.Y., Kim J.H., Roh J.K., Lee K.S., Min J.S., Kim B.S., et al. Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. Breast Cancer Res Treat 43 (1997) 175-181
57. Himelstein B.P., Canete-Soler R., Bernhard E.J., Dilks D.W., and Muschel R.J. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 14 (1994) 246-258
58. Okada H., Woodcock-Mitchell J., and Fujii S. Leukemia inhibitory factor and oncostatin M modulate expression of urokinase plasminogen activator and fibrinogen. Coron Artery Dis 7 8 (1996) 561-567
59. Mullins D.E., and Rohrlich S.T. The role of proteinases in cellular invasiveness. Biochim Biophys Acta 695 (1983) 177-214
60. Brouillet J.P., Dufour F., Lemamy G., Garcia M., Schlup N., Grenier F., et al. Increased cathepsin D in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay. Cancer 79 11 (1997) 2132-2136
61. Duffy M.J., Reilly D., Nugent A., McDermott E., Faul C., Fennelly J.J., et al. Evaluation of proteolytic enzymes implicated in cancer metastasis as prognostic markers in breast cancer. Eur J Surg Oncol 18 11 (1992) 21
62. Thomssen C., Schmidt M., Goretzki L., Oppelt P., Pache L., Dettmar P., et al. Prognostic value of the cysteine proteases cathepsins B and L in human breast cancer. Clin Cancer Res 1 (1995) 741-746
63. Foekens J.A., Kos J., Peters H.A., Krasovec M., Look M.P., Cimerman N., et al. Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 16 3 (Mar 1998) 1013-1021
64. Xing R., Addington A.K., and Mason R.W. Quantification of cathepsins B and L in cells. Biochem J 332 Pt 2 (Jun 1998) 499-505
65. Gerber A., Welte T., Ansorge S., and Buhling F. Expression of cathepsins B and L in human lung epithelial cells is regulated by cytokines. Adv Exp Med Biol 477 (2000) 287-292
66. Couissi D., Dubois V., Remacle C., Schonne E., and Trouet A. Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Clin Exp Metastasis 15 4 (Jul 1997) 349-360
67. Berchem G., Glondu M., Gleizes M., Brouillet J.P., Vignon F., Garcia M., et al. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 21 (2002) 5951-5955
68. Rochefort H., Garcia M., Glondu M., Laurent V., Liaudet E., Rey J.M., et al. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 291 2 (Feb 2000) 157-170
69. Vetvicka V., Vektvickova J., and Fusek M. Effect of human procathepsin D on proliferation of human cell lines. Cancer Lett 79 2 (May 1994) 131-135
70. Fusek M., and Vetvicka V. Mitogenic function of human procathepsin D: the role of the propeptide. Biochem J 303 3 (1994) 775-780
71. Vetvicka V., Vetvicka J., and Fusek M. Anti-human procathepsin D activation peptide antibodies inhibit breast cancer development. Breast Cancer Res Treat 57 3 (Oct 1999) 261-269
72. Obata N.H., Tamakoshi K., Shibata K., Kikkawa F., and Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 17 (1997) 337-342
73. Kitamura Y., Morita I., Nihei Z., Mishima Y., and Murota S. Effect of IL-6 on tumor cell invasion of vascular endothelial monolayers. Surg Today 27 (1997) 534-541
74. Hamilton J.A., Leizer T., Piccoli D.S., Royston K.M., Butler D.M., and Croatto M. Oncostatin M stimulates urokinase-type plasminogen activator activity in human synovial fibroblast. Biochem Biophys Res Commun 180 2 (1991) 652-659
75. Wijelath E.S., Carksen B., Cole T., Chen J., Kothari S., and Hammond W.P. Oncostatin M induces basic fibroblast growth factor expression in endothelial cells and promotes endothelial cell proliferation, migration and spindle morphology. J Cell Sci 110 (1997) 871-879
76. Lu C., Rak J.W., Kobayashi H., and Kerbel R.S. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cll lines derived from advanced-stage lesions. Cancer Res 53 (1993) 2708-2711
77. Koskela K., Pelliniemi T.T., Remes K., Rajamaki A., and Pulkki K. Serum oncostatin M in multiple myeloma: association with prognostic factors. Br J Haematol 96 (1997) 158-160
78. Gibbs P., Chen Q., and Robinson W.A. Effects of oncostatin M and Tamoxifen on human melanoma cells. Melanoma Res 8 3 (1998) 221-226
79. Mori S., Murakami-Mori K., and Bonavida B. Oncostatin M (OM) promotes the growth of DU145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM receptor. Anticancer Res 19 (1999) 1011-1015
80. Purohit A, Ghilchik MW, Duncan L, Wang DY, Singh A, Walker MM, and Reed MJ. Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metab 80(10), 3052-3058.
81. Zhao Y., Nichols J.E., Bulun S.E., Mendelson C.R., and Simpson E.R. Aromatase P450 gene expression in human adipose tissue. J Biol Chem 270 27 (1995) 16449-16457
82. Repovic P., Constance Y.F., Gladson C.L., and Benveniste E.N. Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells. Oncogene 22 (2003) 8117-8124